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Abstract 
 
 
Background: Interferons (IFN) are cytokines typically induced upon viral infection, but are 
constitutively expressed also in the absence of acute infection. The physiological role of 
autocrine and paracrine IFN signaling however remains poorly understood, and its function in 
glioblastoma has not been explored in depth. 
Methods: Using RNA interference-mediated gene silencing we characterized constitutive 
type I IFN signaling and its role in human glioma cells. 
Results: We observed constitutive expression of pSTAT1 and MxA, a classical IFN-response 
marker, in the absence of exogenous IFN-β. In vivo, we found higher MxA expression in 
gliomas than in normal tissue suggesting that IFN signaling is constitutively active in these 
tumors. To demonstrate the presence of an autocrine type I IFN signaling loop in glioma cells 
in vitro, we first confirmed the expression of the type I receptor, IFNAR1/2, and its ligands, 
IFN-α and IFN-β. siRNA-mediated receptor gene silencing resulted in reduced expression of 
MxA at mRNA and protein level, as did gene silencing of the ligands, corroborating the 
hypothesis of an autocrine signaling loop in which type I IFN induce intracellular signaling 
through IFNAR1/2. On a functional level, following IFNAR1 or IFNAR2 gene silencing, we 
observed reduced PD-L1 and MHC class I and II expression as well as an enhanced 
susceptibility to NK immune cell lysis, suggesting that autocrine IFN signaling contributes to 
the immune evasion of glioma cells. 
Conclusions: Our findings point to an important role of constitutive IFN signaling in glioma 
cells by modulating their interaction with the microenvironment.  
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Importance of the study:  
 
 
Interferons (IFN) might be constitutively expressed also in the absence of acute infection 
thereby regulating various physiological processes such as cellular proliferation and 
differentiation, cell viability as well as immune cell function. However, their role in 
glioblastoma, especially in glioma-initiating cells, has not been investigated in detail.  
Here we show that IFN signaling is constitutively active in gliomas in vitro and in vivo. We 
demonstrate the presence of an autocrine signaling loop in which the type I IFN, IFN-α and 
IFN-β, induce intracellular signaling through the type I IFN receptor, IFNAR1/2. On a 
functional level, we define the potential impact of constitutive IFN signaling on the 
immunogenicity of glioma cells. IFNAR1/2 gene silencing reduces PD-L1 and MHC class I 
and II expression and enhances susceptibility to immune cell lysis, suggesting that 
constitutive IFN signaling acts as a negative regulator of anti-tumor immune responses in 
gliomas. 
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Introduction 
 
Gliomas are intrinsic brain tumors which represent a major clinical challenge. Despite intense 
therapeutic efforts, these tumors typically progress and ultimately result in neurological 
deterioration and death. This unfavorable prognosis reflects the biological properties of 
glioma cells which are paradigmatic for various hallmarks of cancer such as invasive growth, 
impaired immunogenicity and resistance to various apoptotic stimuli 1,2. The underlying 
mechanisms are only partially understood but is has become clear that various alterations on 
the genetic and molecular level contribute to the malignant behavior of glioma cells. 
Furthermore, the existence of a subpopulation of cells that harbor stem-cell characteristics 
within gliomas suggests that a rather small percentage of the tumor cells may maintain tumor 
growth 3. With regard to stem cells, type I interferons (IFN) such as IFN-α or IFN-β have 
gained increasing interest within the last years. Constitutive type I IFN signaling may be 
important for the maintenance and mobilization of hematopoietic stem cells within the niche 
since either the absence of constitutive IFN signaling or prolonged elevated IFN signaling 
deplete the hematopoietic stem cell niche. Upon chronic IFN signaling, an induction of 
proliferation was observed in dormant hematopoietic stem cells, a finding that might be of 
relevance also for cancer stem cells 4,5. 
IFN are produced by most nucleated cells and their signaling is mediated through a common 
cell surface type I IFN receptor complex composed of two subunits, IFNAR1 and IFNAR2 6,7. 
IFNAR2 is supposed to be responsible for ligand binding, while IFNAR1 holds very weak 
ligand binding affinity, but induces intracellular signaling cascades 8-10. The ligand-mediated 
association of the two subunits promotes a signaling cascade that results in the 
phosphorylation of IFNAR1 and creation of a docking site for STAT2. STAT2 
phosphorylation creates a docking site for STAT1 which enables phosphorylation of STAT1 
7. The STATs either form homodimers of STAT1, or heterodimers of STAT1 and STAT2 
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which then translocate to the nucleus to induce expression of IFN-stimulated genes. 
Additionally, type I IFN can activate other members of the STAT family such as STAT3, 
STAT4, STAT5 or STAT6 11.  
Activity of the IFN-signaling pathway also leads to the induction of myxovirus A (MxA) 
protein expression, a cytoplasmic GTPase with antiviral activity 12. The genes activated by 
IFN do not only play a crucial role in cellular processes protecting from viral infections, but 
also in modulating general immune responses, cell proliferation and cell survival 13. 
Moreover, IFN signaling might be of relevance also in different tumor types since mutations, 
preventing the production of or altering the responsiveness to IFN, have been observed in 
numerous malignancies like leukemia or melanoma, thus possibly representing a survival 
advantage for tumor cells 14,15. In addition, the efficacy of type I IFN as an anti-cancer 
treatment is affected by constitutive IFN expression 16. Thus, based on the involvement of 
type I IFN in various cellular processes, we aimed at characterizing constitutive IFN signaling 
and its role in glioma cells including glioma cells with stem cell properties.
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Materials and methods 
 
Cell lines and reagents 
The human long-term cell (LTC) lines U87MG and T98G were obtained from the American 
Type Culture Collection (Manassas, VA), and LN-18, LN-428, D247MG, LN-319, A172, 
LN-308 and LN-229 cells were kindly provided by N. de Tribolet (Lausanne, Switzerland). 
The glioma-initiating cells (GIC) T-269, T-325, S-24, ZH-161 and ZH-305 were isolated from 
tumors resected in Tübingen, Germany (T-269, T-325), Stuttgart, Germany (S-24), or Zurich, 
Switzerland (ZH-161, ZH-305) and were used during the first passages 17. Cells were 
authenticated regularly at the Leibniz Institute DSMZ-German Collection of Microorganisms 
and Cell Cultures, Braunschweig, Germany by Short Tandem Repeat (STR) analysis, lastly in 
2013 (LTC) and in 2016 (GIC). All LTC were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM, Invitrogen, Paisley, UK) containing 10% fetal calf serum (FCS, Invitrogen) 
and 2 mM glutamine. The GIC cultures were maintained in Neurobasal (NB) medium 
(Invitrogen) supplemented with B-27 supplement (20 µl/ml), Glutamax (10 µl/ml) 
(Invitrogen), fibroblast growth factor (FGF)-2, epidermal growth factor (EGF) (20 ng/ml 
each; Peprotech, Rocky Hill, PA) and heparin (32 IE/ml; Ratiopharm, Ulm, Germany). The 
natural killer cell line NKL was obtained from M.J. Robertson (Indiana University School of 
Medicine, Indianapolis, IN) and cultured in RPMI 1640 medium (Invitrogen) supplemented 
with 15% FCS, 2 mM glutamine and 50 U/ml interleukin (IL)-2 (Peprotech). Recombinant 
IFN-β1b was purchased from AbD Serotec (Düsseldorf, Germany). Antibodies to human 
CD45 (clone 2B11) was from DakoCytomation (Hamburg, Germany), STAT-1 and phospho-
STAT-1 (Tyr701) were purchased from Cell Signaling (Boston, MA), PE-labeled anti-
IFNAR2 from PBL Assay Science (Piscataway, NJ, USA), anti-MHC-I (clone W/32) and 
anti-HLA-DR (clone L243) were kindly provided by S. Stevanović (Tübingen, Germany) 18, 
Antibodies to NKG2D ligands (NKG2DL) were provided by A. Steinle (Frankfurt, Germany), 
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BV421 anti-human PD-L1 (clone MIH1) was obtained from BD Biosciences (Franklin Lakes, 
NJ), and actin antibody was purchased from Santa Cruz (Dallas, TX). The MxA antibody 
used for immunoblot analysis in Fig. 1B was provided by J. Pavlovic (Zurich, Switzerland). 
All other immunoblot analyses were performed with a MxA antibody provided by O. Haller 
(Freiburg, Germany). The MxA antibody for immunohistochemistry and immunofluorescence 
was purchased from Thermo Fisher Scientific (Waltham, MA).  
 
Real-time PCR  
Total RNA was prepared using the NucleoSpin RNA II System (Macherey-Nagel AG, Düren, 
Germany) and transcribed into cDNA using the High Capacity cDNA Reverse Transcription 
Kit from Applied Biosystems (Foster City, CA). Gene expression was measured in an ABI 
Prism 7000 Sequence Detection System (Applied Biosystems) with SYBR Green Master Mix 
(Thermo Fisher Scientific). The conditions for the PCR reactions were: 40 cycles, 95°C/15 
sec, 60°C/1 min, using the following specific primers (Microsynth AG, Balgach, 
Switzerland): GAPDH forward: 5'-CTCTCTGCTCCTCCTGTTCGAC-3’ (NM_002046.4, nt 
100-121), GAPDH reverse: 5’-TGAGCGATGTGGCTCGGC T -3’ (NM_002046.4, nt 150-
168); IFNAR1 forward: 5'-TATGCTGCGAAAGTCTTCTTGAG-3' (NM_000629.2, nt 1510-
1532), IFNAR1 reverse: 5'-TCTTGGCTAGTTTGGGAACTGTA-3’ (NM_000629.2; nt 1726-
1748); IFNAR2 forward: 5'-TCTTGAGGCAAGGTCTCGCTA-3’ (NM_207584.2, nt 1195-
1215), IFNAR2 reverse: 5'-CAGGGATGCACGCTTGTAATC-3’ (NM_207584.2, nt 1320-
1340); IFN-α14 forward: 5'-TCTTCGGGATTCCCAATGGC-3' (NM_002172.2; nt 30-49), 
IFN-α14 reverse: 5'-CTTGACTTGCAGCTGAGCAC-3' (NM_002172.2; nt 81-100); IFN-β1 
forward: 5'-AGTAGGCGACACTGTTCGTG-3' (NM_002176.3; nt 67-86), IFN-β1 reverse: 
5-AGCCTCCCATTCAATTGCCA-3' (NM_002176.3; nt 221-240); MxA forward: 5`- 
TGGAGATCAGCTCCCGAGATG-3' (NM_001144925.1, nt 512-532), MxA reverse: 5'- 
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ATTGCCCACAGCCACTCTG-3' (NM_001144925.1, nt 570-588). Data analysis was done 
using the ΔΔCT method for relative quantification.  
 
RNA interference-mediated gene silencing  
For transient transfections, glioma cells were seeded in a six-well plate and transfected with 
100 nM of specific or scrambled control small interfering (si) RNA by electroporation using 
the NeonTM Transfection System (Invitrogen). Control as well as MxA, IFNAR1 and IFNAR2 
siRNA oligonculeotides were purchased from Thermo Scientific using siGENOME 
SMARTpool. siRNA oligonucleotides targeting IFN-α14, IFN-α17 or IFN-β1 were obtained 
from Qiagen.  
 
Flow cytometry  
Cells were detached using accutase (PAA, Vienna, Austria), incubated with primary antibody 
for 30 min at 4°C followed by an R-phycoeythrin-conjugated secondary antibody labeling 
step for another 30 min in case of not unlabeled primary antibody. Fluorescence was detected 
in a Cyan flow cytometer (Beckman Coulter, Nyon, Switzerland) or a BD FACSVerseTM 
flow cytometer. Signal intensity was calculated as the ratio of the median fluorescence of the 
specific antibody and the isotype control antibody (specific fluorescence index (SFI)).  
 
Immune cell lysis assay 
Immune-mediated glioma cell lysis was determined using a flow cytometry-based 
cytotoxicity assay 17. Target cells were stained with PKH-26 (Sigma-Aldrich) for 3 min and 
then co-incubated with NKL effector cells at different effector to target (E:T) ratios as 
indicated for 4 h. Subsequently, live/dead staining was performed with Zombie Aqua Fixable 
Viability Kit (BioLegend, San Diego, CA) followed by assessment of target cell lysis by flow 
cytometry. Specific cell lysis was expressed as percentage of dead cells within the PKH-26-
  
10 
 
positive target cells, corrected for spontaneous background lysis. For PD-L1 blocking 
experiments, T-325 or ZH-161 cells were incubated 1 h prior and during co-incubation with 
10 µg/ml of anti-PD-L1 (clone 29E.2A3, Biolegend). 
 
Immunoblot analysis  
The cells were treated as indicated and lysed in radioimmunoprecipitation assay (RIPA) lysis 
buffer (10 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% sodium 
dodecyl sulfate) containing phosphatase inhibitor cocktails 2 and 3 and protease inhibitor 
(Roche Diagnostics, Grenzach-Wyhlen, Germany). Thirty μg of protein per lane were mixed 
with Laemmli buffer containing β-mercaptoethanol and analyzed by immunoblot. 
Visualization of protein bands was accomplished using horseradish peroxidase-coupled 
secondary antibodies (Santa Cruz) and enhanced chemiluminescence (Thermo Fisher 
Scientific).  
 
Immunohistochemistry 
Immunohistochemistry was carried out on tissue microarrays (TMA) with tissue specimens of 
normal brain or of gliomas of different World Health Organization (WHO) grades of 
malignancy that were kindly provided by Karl Frei (Department of Neurosurgery)19. TMA 
sections were stained using the rabbit polyclonal primary antibody to MxA (1:200) and 
visualized using anti-rabbit secondary antibody with Imm Pact DAB kit (Vector, Burlingame, 
CA). The intensity of staining and the percentage of stained tumor cells on the TMA were 
quantified by H scoring 20,21. For co-stainings, TMA sections were stained with primary 
antibodies to MxA (rabbit, 1:200) and CD45 (mouse, 1:50) and visualized using mouse anti-
rabbit IgG-HRP secondary antibody (Santa Cruz) with ImmPact DAB kit (Vector 
Laboratories, Burlingame, Ca) followed by anti-mouse IgG-AP secondary antibody (Vector 
Laboratories) with HighDef greenIHC chromogen kit (Enzo, Lasuen, Switzerland). 
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Immunofluorescence 
Five x 105 cells were cytospun onto a glass slide, dried for 30 min, fixed in ice-cold methanol 
for 10 min and permeabilized with 0.5 % Triton X100. Subsequently, cells were stained using 
the rabbit polyclonal primary antibody to MxA (1:100), visualized using an AF488-
conjugated secondary antibody (Southern Biotech, Birmingham, AL) and mounted in 
Vectashield Mounting Media with DAPI (Burlingame, CA). 
 
TCGA analysis 
Kaplan-Meier analysis of survival probability for the glioblastoma 540 - MAS5.0 - u133a 
dataset (n=540) within the TCGA database (http://cancergenome.nih.gov) was done using the 
R2: microarray analysis and visualization platform (http://r2.amc.nl) and median MxA 
expression was selected as scan cut-off mode. 85 samples of this dataset classified according 
to glioblastoma subtype 22 were analyzed for MxA expression using the subtype track mode 
23. Correlation analysis for the glioblastoma 540 - MAS5.0 - u133a dataset (n=540) or the 
Glioma - French - 284 - MAS5.0 - u133p2 dataset (n=284) was done using the module for 
correlation of 2 genes of the R2: microarray analysis and visualization platform 
(http://r2.amc.nl). Samples of the Glioma - French - 284 - MAS5.0 - u133p2 dataset (n=284) 
were grouped according to the different WHO grades of malignancy and analyzed for MxA 
expression using the histology subtype track mode. 
 
Data analysis  
Data are representative of at least two independent experiments. If not indicated otherwise, 
analysis of significance was performed using the two-tailed Student’s t-test (* p < 0.05; ** p 
< 0.01). 
  
12 
 
Results 
 
STAT1 phosphorylation and MxA expression indicate autocrine IFN signaling in glioma cells  
Binding of type I IFN to their cognate cell surface receptor induces down-stream signaling 
through STAT1/STAT2 and Jak1/Tyk2 kinases. To demonstrate constitutive IFN signaling as 
well as responsiveness to exogenous IFN, we assessed expression of MxA, an established 
marker for activation of the classical IFN-α/β signaling pathway. Highest constitutive MxA 
levels were seen in T-325 and ZH-161 GIC cells, and MxA mRNA levels increased in all cell 
lines upon exposure to IFN-β (Fig. 1A). Several glioma cell lines displayed constitutive MxA 
protein expression with T-325 and ZH-161 GIC having the highest constitutive MxA protein 
levels. Exposure to IFN-β induced MxA expression in all cell lines investigated (Fig. 1B,C). 
Furthermore, we determined the basal levels of phosphorylated STAT1 as well as the 
induction of STAT1 phosphorylation upon exposure to recombinant IFN-β. We observed 
constitutive STAT1 phosphorylation to a variable degree in all cell lines and an induction of 
STAT1 phosphorylation upon exposure to exogenous IFN-β (Fig 1B). 
To rule out an artificial effect of the cell culture medium in the induction of IFN-β-target 
genes such as MxA, we cultured LTC in NB medium: here, no induction of MxA was 
observed; further, culturing GIC in serum-free (SF) or complete DMEM medium had no 
major consistent effect on MxA levels (Fig. 1D), but interfered with the sphere culture 
phenotype at longer incubation times (data not shown). 
 
The IFN-β signaling pathway is activated in glioma cells in vivo 
We then explored whether IFN signaling is constitutively active in gliomas in vivo. To this 
end, we analyzed the expression of the IFN-specific target gene, MxA, using data from glioma 
patients of different WHO grades deposited in the TCGA database. There was a trend for 
increased MxA mRNA levels with increasing WHO grade with highest levels in glioblastoma 
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(Fig. 2A, left). No differential expression was observed when MxA levels were examined in 
the molecular subtypes classified by Verhaak et al. 22 (Suppl. Fig. 1A). The survival of 
glioblastoma patients with tumors expressing high MxA levels was shorter when the median 
was used as cut-off (Fig. 2A, right). We observed a strong correlation of MxA expression 
with the IFN response genes STAT1, STAT2, STAT3 and IFN regulatory factor 7 (IRF7), but 
not with IFNAR1, IFNAR2 or type I IFN on the transcriptional level (Suppl. Fig. 1B). To 
confirm the results obtained by the TCGA database interrogation, we analyzed MxA protein 
levels by immunohistochemistry on a TMA of gliomas of different WHO grades. MxA was 
mainly found in the cytoplasm. As shown in Fig. 2B and C, MxA protein levels increased 
with WHO grade. Again, highest MxA levels were observed in glioblastoma. Similarly, 
pSTAT1 significantly correlated with MxA protein levels (Fig. 2B, right). Since IFN are also 
produced by activated immune cells, we looked for the presence of MxA-expressing immune 
cells in the glioma tissue specimens on the TMA, too. Despite the overall low numbers, we 
noticed an increase of CD45+MxA+ immune cells with histological grade (Fig. 2D).  
 
IFN receptors are expressed by glioma cells  
IFN-α and IFN-β mediate their effects through the type I IFN heterodimer cell surface 
receptor complex composed of two subunits, IFNAR1 and IFNAR2. First, we confirmed that 
IFNAR1 and IFNAR2 are expressed on a transcriptional level in the panel of glioma cells 
tested (Fig. 3A, left). Moreover, as observed previously, only IFNAR2, but not IFNAR1, was 
detectable by flow cytometry using currently available antibodies (Fig. 3A, right) 24. 
To confirm that constitutive MxA expression in GIC depends on signaling through IFNAR, 
we silenced both receptor subunits using RNA interference in T-325 and ZH-161 cells. The 
knock-down efficacy was confirmed at the mRNA level for both receptor subunits (Fig. 3B, 
left) and additionally at the protein level for IFNAR2 (Fig. 3B, right).  
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Silencing of IFNAR1 or IFNAR2 resulted in reduced MxA mRNA levels (Fig. 3B, left). In 
line with these findings, STAT1 phosphorylation and MxA protein levels were reduced upon 
silencing of IFNAR1 or IFNAR2 in both cell lines (Fig. 3C).  
 
Identification of ligands to the type I IFN receptor in glioma cells 
Based on the results obtained with IFN receptor silencing, it seemed most likely that 
endogenous IFN propagates the signaling through IFNAR. To identify the ligands, we 
determined the expression of IFN-α and IFN-β at mRNA level in glioma cell lines. Both 
ligands were expressed at variable levels in the panel of glioma cells tested (Fig. 4A). 
Silencing of IFN-α or IFN-β by RNA interference resulted in decreased MxA mRNA 
expression (Fig. 4B), whereas on the protein level, silencing of IFN-α or IFN-β led to reduced 
MxA and pSTAT1 protein levels, more prominently by silencing of IFN-β than IFN-α, 
confirming an autocrine IFN signaling loop in glioma cells (Fig. 4C).  
 
Autocrine IFN signaling impairs the immunogenicity of glioma cells 
Finally, we defined the role of constitutive IFN signaling in human GIC on a functional level 
focusing on immunological aspects. Disruption of autocrine IFN signaling using siRNA-
mediated silencing of IFNAR1 and IFNAR2 in T-325 or ZH-161 cells resulted in decreased 
programmed death-ligand 1 (PD-L1) cell surface expression, whereas addition of exogenous 
recombinant IFN-β increased PD-L1 cell surface levels (Fig. 5A). Accordingly, using a 
TCGA database interrogation, we observed a significant correlation between MxA and PD-L1 
mRNA expression levels in vivo in glioma patients (Fig. 5B). Moreover, MxA levels 
correlated with the T cell activation marker CD69, but not with CD25 or PD-1 (Suppl. Fig. 
2A). In order to define whether MxA is a regulator of PD-L1 expression, we silenced MxA 
using RNA interference which, however, did not affect PD-L1 cell surface levels (Suppl. Fig. 
2B). Silencing of IFNAR1 and IFNAR2 by RNA interference did not influence NKG2DL 
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levels but resulted in decreased MHC class I and class II cell cell surface expression (Suppl. 
Fig. 3A, Fig. 5C). In line with these data, we found a significant correlation between MxA 
and MHC class I and II mRNA expression in vivo when data from glioblastoma patients 
deposited in the TCGA database were analyzed (Suppl. Fig. 3B). MxA mRNA levels also 
correlated with the expression of the non-classical MHC molecules HLA-E and HLA-G 
which have been described as mediators of glioma immune escape (Suppl. Fig. 3C) 25,26. Most 
importantly, ZH-161 glioma cells were more susceptible to NKL cell-mediated immune cell 
lysis upon IFNAR gene silencing corroborating the assumption that constitutive IFN signaling 
acts as a negative regulator of anti-tumor immune responses (Fig. 5D). Inhibition of the PD-1 
pathway using blocking PD-L1 antibodies did not alter NKL cell-mediated lysis of glioma 
cells (Suppl. Fig. 3D). 
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Discussion 
 
IFN-β has been used as a therapeutic agent against glioblastoma in small clinical trials which 
were largely interpreted as promising 27. However, the molecular mechanisms responsible for 
potential IFN-mediated effects on glioma cells in vivo have remained uncertain and the effect 
of IFN-β on the more resistant GIC population is subject of current research. Importantly, it 
has been demonstrated that the efficacy of type I IFN as anti-tumor drugs is affected by 
constitutive IFN signaling in that the expression and activation of the IFN-stimulated gene 
factor 3a (ISGF3a) correlated with cellular IFN responsiveness 15,16. Moreover, chronic IFN 
signaling induces the proliferation of dormant hematopoietic stem cells, which might also be 
relevant for cancer stem cells and their impact on sustained tumor growth 16. Based on these 
considerations, we investigated the role of autocrine IFN-β signaling in glioma cells including 
GIC. 
We observed constitutive STAT1 phosphorylation in most glioma cell lines and increased 
phosphorylation after exposure to exogenous IFN-β (Fig. 1B). Constitutively activated STAT 
proteins have been attributed a role in the malignant phenotype of many tumors including 
glioblastoma 28 and constitutively activated STATs have been implicated in radioresistance 
29,30. While STATs can be activated by IFN but also other cytokines or growth factors, MxA 
may be an ideal candidate to specifically assess the activity of the IFN signaling pathway 12,28. 
Although single studies suggested a potential role of α-defensin 31 and interleukins 32 in the 
induction of MxA, it is widely accepted that it is specifically induced by IFN 33. Thus, as a 
suitable readout for the presence of IFN activity, we examined the levels of MxA protein in 
glioma cells. Constitutive MxA expression was mainly observed in GIC lines (Fig. 1B). These 
results correlated with qPCR results, which demonstrated higher MxA mRNA expression 
levels in T-325 and ZH-161 GIC lines than in other cell lines (Fig. 1A). Since LTC and GIC 
lines are cultured under different conditions, we asked whether the cell culture medium would 
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influence constitutive MxA expression. Culturing LTC in stem cell medium neither induced 
nor repressed MxA levels in any cell line while FCS-containing complete medium increased 
(T-325) or decreased (ZH-161) MxA expression in GIC lines (Fig. 1D). Importantly, GIC 
change their phenotype in FCS-containing medium and become adherent, thus, the effect of 
this medium on MxA expression might be a consequence of induced cell differentiation rather 
than a direct response to medium exchange. Based on these findings, and taking into account 
that not all GIC lines express MxA, we concluded that MxA expression is not an effect of cell 
culture medium conditions.  
We then analyzed MxA levels in vivo and observed higher expression in gliomas than in 
normal tissue, with highest levels in glioblastoma, suggesting that IFN signaling is 
constitutively active also in gliomas in vivo (Fig. 2). No differential expression between the 
different subtypes classified by Verhaak 22 was observed (Suppl. Fig. 1) suggesting that this is 
a rather general pathway. Survival analyses of glioblastoma patients from the TCGA database 
revealed inferior survival for patients with tumors with increased MxA expression, suggesting 
an impact of constitutively active IFN signaling on the malignant phenotype of these tumors. 
Similarly, overexpression of IFN/STAT1-related genes may be predictive for poor survival in 
the proneural subtype of glioblastoma 28,34. 
We then confirmed that IFNAR1 and IFNAR2 are expressed in all cell lines and subsequently 
performed siRNA-mediated gene silencing of IFNAR1, IFNAR2 or both subunits in T-325 and 
ZH-161 cells. Receptor silencing led to reduced expression of MxA at mRNA and protein 
level (Fig. 3B, C). Moreover, gene silencing of the ligands, IFN-α and IFN-β, resulted in 
decreased MxA expression, too, confirming an autocrine signaling loop in which type I IFN 
mediate the induction of MxA through IFNAR1/2 (Fig. 4B, C). There was no correlation of 
IFN receptor or IFN-β expression with MxA levels in glioblastomas in the TCGA database in 
vivo. Hence, a variable activation status of the receptor subunits and/or their ligands and the 
involvement of other, yet undescribed signaling pathways, might explain this observation. 
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Further limitations of TCGA analyses include the inability to determine whether mRNA 
species stem from tumor cells or infiltrating host cells which is particularly relevant when 
exploring immunological aspects of the disease. On a TMA, we observed generally low, but 
increasing numbers of tumor-infiltrating lymphocytes with the WHO grade, suggesting that 
IFN signaling in glioma cells might be induced in an autocrine and paracrine manner (Fig. 
2D). 
Although typically expressed only at low levels, IFN may exert strong effects on various 
tissues 16. Beside their role in the protection of cells from viral infections, constitutive IFN 
signaling seems to be involved in various cellular responses to other cytokines and growth 
factors as well as the proper regulation of immune responses 35-37. Therefore, we aimed at 
defining the functional impact of the observed constitutive IFN signaling on the 
immunogenicity of glioma cells. Here, we noticed reduced PD-L1 as well as MHC class I and 
II expression upon IFNAR1 or IFNAR2 silencing in GIC, suggesting that IFN signaling in 
these cells may be involved in the interaction between glioma cells and the microenvironment 
(Fig. 5). Additionally, MxA mRNA levels correlated with MHC class I and II molecules and 
with the non-classical MHC molecules HLA-E and HLA-G in vivo (Suppl. Fig. 3B, C). PD-
L1 is expressed by glioma cells in vitro and in vivo and confers immunosuppressive effects by 
promoting T cell apoptosis and induction of regulatory T cells 38. Similarly, high MHC class I 
and II expression can inhibit innate immune responses against tumor cells 39. In line with our 
findings, a role for endogenous IFN-β in the regulation of PD-L1 expression has been 
described in neurons 40. The observation that RNA interference-mediated silencing of MxA 
did not alter PD-L1 expression indicates that PD-L1 expression is regulated by the IFN 
pathway  of MxA (Suppl. Fig. 2B). Moreover, IFN strongly activate monocytes/macrophages 
and upregulate MHC class I and II expression 41,42. Furthermore, the expression of the non-
classical MHC molecules HLA-E and HLA-G has been linked to immune-inhibitory effects in 
gliomas. Here, HLA-E mainly inhibits NK cell-mediated lysis while HLA-G interferes with 
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CD4 and CD8 T cell activity 25,26. Accordingly, abrogation of IFN signaling in glioma cells by 
IFNAR1 and IFNAR2 gene silencing made these cells more susceptible to immune cell killing 
(Fig. 5). Since inhibition of the PD-1 pathway using blocking PD-L1 antibodies did not alter 
NKL cell-mediated lysis of glioma cells (Suppl. Fig. D), it is tempting to speculate that the 
increased susceptibility to NKL cell-mediated lysis upon IFNAR gene silencing results from 
decreased MHC class I and class II expression. Hence, our findings suggest that the 
upregulation of MHC molecules due to constitutive IFN signaling may impair anti-tumor 
immune responses by NK cells.  
Interruption of endogenous IFN signaling did not result in increased NKG2DL expression, 
which is line with previous findings indicating that exposure to exogenous IFN-β had no 
effect or decreased NKG2DL cell surface levels 43 (Suppl. Fig. 3A). Thus, whether the boost 
of immune responses, induced by the treatment with recombinant exogenous IFN-β, results in 
a net-immune stimulating or net-inhibitory effect might be cell line and context dependent.  
In summary, we describe the presence of constitutive IFN signaling in glioma cells which 
may have an important role in the interaction of these cells with the microenvironment. A 
more detailed understanding of this intrinsic IFN activity, particularly in the stem cell 
compartment of gliomas, may lay a basis for the therapeutic targeting of this pathway in order 
to interfere with the continuous growth of these tumors.  
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Figure legends 
 
Figure 1: IFN-β target genes are expressed in glioma cells. A. The human LTC LN-18, 
LN-428, D247MG, LN-319, A172, U87MG, T98G, LN-308 and LN-229, and the GIC T-325, 
T-269, ZH-161, ZH-305 or S-24 were cultured without or with IFN-β (150 IU/ml) for 48 h 
and MxA mRNA expression levels were determined using real-time PCR (median expression 
levels ± SE are shown from 3 independent experiments). B. The cells were treated as in (A). 
Whole cell lysates were subsequently analyzed for pSTAT1, STAT1 and MxA protein levels 
by immunoblot using actin as a loading control (1 out of 2 independent experiments is 
shown). C. LN-308 or ZH-161 cells, untreated or exposed to IFN-β (150 IU/ml) for 48 h, 
were analyzed for MxA protein levels by immunofluorescence (scale bar, 50 µm). D. LN-308, 
LN-229, T-325 or ZH-161 cells were cultured in various medium conditions as indicated for 
48 h (SF, serum-free DMEM medium; NB, Neurobasal medium). Whole cell lysates were 
assessed for MxA expression levels using immunoblot. Actin was used as loading control.  
 
Figure 2: MxA is expressed in gliomas in vivo. A. MxA mRNA expression levels in 
gliomas of different WHO grades were analyzed using data from the TCGA database (left). 
Overall survival analysis within the TCGA database for glioblastoma patients with high 
versus low MxA expression was performed by Kaplan-Meier analysis. The median was used 
as cut-off (right). B. MxA protein levels were assessed by immunohistochemistry on a glioma 
tissue microarray (TMA) and quantified by H scoring (left). pSTAT1 protein levels were 
analyzed by immunohistochemistry on a TMA and quantified by H scoring. A correlation 
analysis of pSTAT1 H scores with MxA H scores is shown (right). C. Representative images 
of normal brain and glioblastoma specimens with low, intermediate or high MxA levels are 
shown (scale bar, 100 µm or 10 µm for 20x or 40x magnification, respectively). D. 
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MxA/CD45 co-staining was performed on a glioma TMA and the number of double-positive 
cells was counted. 
 
Figure 3: MxA expression in human GIC depends on signaling through IFNAR1 and 
IFNAR2. A. Basal expression levels of IFNAR1 and IFNAR2 were assessed in LN-18, LN-
428, D247MG, LN-319, A172, U87MG, T98G, LN-308 and LN-229, T-325, T-269, ZH-161, 
ZH-305 or S-24 cells by real-time PCR (left) (median expression levels  ± SE are shown from 
2 independent experiments). Cell surface IFNAR2 protein was analyzed by flow cytometry (1 
out of 2 independent experiments is shown). Isotype control antibody (grey) and specific 
antibody (black) are shown in the histograms (right). B. siRNA-mediated gene silencing of 
IFNAR1 (si_IFNAR1si), IFNAR2 (si_IFNAR2si) or IFNAR1 and IFNAR2 in parallel 
(si_IFNAR1/2) in T-325 or ZH-161 cells was performed by electroporation and confirmed for 
IFNAR1,  IFNAR2 and MxA by real-time PCR 24 h post transfection (median expression 
levels ± SE are shown from 3 independent experiments) and for IFNAR2 by flow cytometry 
at 48 h following transfection. Isotype control antibody (grey) and specific antibody (black) 
are shown in the histograms. C. pSTAT1, STAT1 and MxA levels of control, si_IFNAR1, 
si_IFNAR2 or double knock-down cells (si_IFNAR1/2) were determined 48 h after 
transfection by immunoblot (1 out of 3 independent experiments is shown).  
 
Figure 4: Glioma-derived IFN-α or IFN-β induces autocrine signaling. A. IFN-α or IFN-β 
mRNA expression levels were determined in LN-308, LN-229, T-325, T-269, ZH-161, ZH-
305 or S-24 cells using real-time PCR (median expression levels ± SE are shown from 2 
independent experiments). B, C. siRNA-mediated gene silencing of IFN-α (si_IFN-α) or IFN-
β (si_IFN-β) was performed using electroporation in T-325 or ZH-161 cells. MxA mRNA 
expression was determined 24 h post transfection by real-time PCR (median expression levels 
± SE are shown from 2 independent experiments) (B), while pSTAT1, STAT1 and MxA 
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protein levels were assessed at 48 h following transfection by immunoblot. Actin was used as 
a loading control (1 out of 3 independent experiments is shown) (C).  
 
Figure 5: Constitutive IFN signaling impairs the immunogenicity of glioma cells. A. 
siRNA-mediated silencing of IFNAR1/2 or transfection with control oligonucleotides was 
performed in T-325 or ZH-161 using electroporation (top), or the cells were exposed to 150 
IU/ml IFN-β or not (bottom). Cell surface PD-L1 protein levels were assessed after 72 h by 
flow cytometry (1 out of 3 independent experiments is shown). Isotype control antibody 
(grey) and specific antibody (black) are shown in the histograms. B. Correlation analysis of 
MxA with PD-L1 mRNA expression was performed for glioma patients within the TCGA 
database. Two-tailed Pearson test coefficients (r) and significances (p) are indicated. C, D. 
siRNA-mediated gene silencing of IFNAR1/2 in T-325 or ZH-161 cells was performed by 
electroporation. MHC class I or II cell surface protein levels were determined 48 h post 
transfection by flow cytometry (median expression levels ± SD are shown from 8 independent 
experiments) (C). ZH-161 cells were used as target cells in a 4 h NKL cell lysis assays at 
various effector : target (E:T) ratios as indicated 72 h after transfection. The percentage of 
target cell lysis corrected for spontaneous background lysis is shown (left) (1 out of 4 
independent experiments is shown). The knock-down efficiency for IFNAR1 and IFNAR2 
gene silencing was confirmed by real-time PCR (right) (D).  
